Loading…
Septerna, Inc. is projected to rise to $44.45 by 2027, a +24% move from its current price of $35.93. SEPN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $34.68 | $35.93 | $37.23 | +0.01% |
| Jul 15 | $34.17 | $35.94 | $37.79 | +0.02% |
| Jul 16 | $33.79 | $35.94 | $38.22 | +0.02% |
| Jul 17 | $33.47 | $35.94 | $38.59 | +0.03% |
| Jul 18 | $33.20 | $35.94 | $38.92 | +0.04% |
| Jul 19 | $32.95 | $35.95 | $39.22 | +0.05% |
| Jul 20 | $32.72 | $35.95 | $39.50 | +0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $32.72 | $35.95 | $39.50 | +0.06% |
| Week 2 | $31.49 | $35.97 | $41.09 | +0.11% |
| Week 3 | $30.58 | $35.99 | $42.36 | +0.17% |
| Week 4 | $29.83 | $36.01 | $43.47 | +0.23% |
| Week 5 | $29.20 | $36.03 | $44.47 | +0.28% |
| Week 6 | $28.63 | $36.05 | $45.40 | +0.34% |
| Week 7 | $28.12 | $36.07 | $46.27 | +0.40% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Septerna, Inc. is a clinical-stage biotechnology company focused on discovering and developing G protein-coupled receptor (GPCR) oral small molecule products for endocrinology, immunology and inflammation, and metabolic diseases.
Its programs include the PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and a TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease.
It has a global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc.
in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Septerna, Inc. trades under the symbol SEPN. The current price is $36.40 with a market capitalization of $1.64B and a rank of 2196. The near-term forecast shows a neutral stance for 2026 with an avg price of $36.40 and a min of $23.09, a max of $45.97, and ROI of 0.
The forecast improves to a bullish trajectory from 2027 onward, with the average price rising to $44.74 in 2027, $49.28 in 2028, and $54.85 in 2029, reaching $70.58 in 2030 and continuing higher through 2050 at an average of $437.31. These figures imply meaningful long-term upside, though they are estimates and not guarantees.
Current price and market position anchor the near term, while the year-by-year forecast outlines a clear upward trajectory in average prices and ROI over the coming years and decades. Investors should interpret these projections as directional estimates, not guarantees, and consider the inherent uncertainty in long-horizon forecasts.
A major floor 35.7% below — a decisive break under it would weaken the trend.
The nearest floor, 16.7% below — buyers have tended to step in here.
The nearest ceiling, 5.3% above — a clean break opens room to run.
A major ceiling 18.2% above — clearing it would confirm fresh momentum.
Key SEPN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SEPN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $35.89 | Buy | $36.07 | Sell |
| MA 10 | $35.37 | Buy | $35.60 | Buy |
| MA 20 | $35.44 | Buy | $34.68 | Buy |
| MA 50 | $30.66 | Buy | $31.88 | Buy |
| MA 100 | $28.35 | Buy | $29.28 | Buy |
| MA 200 | $26.22 | Buy | $25.97 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.23 | Neutral |
| Stoch RSI (14) | 26.65 | Neutral |
| CCI (20) | 32.41 | Neutral |
| Williams %R (14) | -43.71 | Info |
| MACD (12,26,9) | -0.13 | Sell |
| ROC (12) | -1.75 | Sell |
| Bollinger %B (20,2) | 0.60 | Neutral |
| Stochastic %K (14) | 56.29 | Neutral |
| TRIX (15) | 0.72 | Buy |
| Awesome (5,34) | 2.61 | Buy |
| Ultimate (7,14,28) | 59.29 | Neutral |
| Momentum (10) | 1.39 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 37.27 | Sell |
| ADX (14) | 21.96 | Buy |
| ATR (14) | 1.23 | Info |
The 30-day technical picture is bullish overall. RSI14 sits at 60, suggesting room to move higher without being overbought.
The 50-day simple moving average is $30.18 and the 200-day simple moving average is $26.01, providing a near-term price framework. Support is at $29.79 and resistance at $37.34, framing a constructive path for tactical moves. The 30-day range spans from a low of $28.87 to a high of $45.89, revealing a broad trading band in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $23.09 | $35.93 | $45.52 | 0% | Neutral | |
| $34.40 | $44.45 | $61.33 | +24% | Bullish | |
| $37.05 | $49.71 | $71.82 | +38% | Bullish | |
| $40.27 | $55.75 | $83.50 | +55% | Bullish | |
| $50.65 | $72.11 | $111.28 | +101% | Bullish | |
| $61.39 | $89.68 | $142.04 | +150% | Bullish | |
| $74.82 | $111.95 | $181.49 | +212% | Bullish | |
| $83.34 | $127.58 | $211.19 | +255% | Bullish | |
| $81.89 | $128.11 | $216.19 | +257% | Bullish | |
| $86.35 | $137.94 | $236.95 | +284% | Bullish | |
| $156.90 | $276.06 | $510.59 | +668% | Bullish | |
| $226.53 | $474.19 | $975.24 | +12.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $23.09 | $35.93 | $43.66 | +0.00% |
| August 2026 | $30.10 | $35.80 | $43.92 | -0.37% |
| September 2026 | $30.15 | $36.20 | $45.05 | +1.11% |
| October 2026 | $30.88 | $37.36 | $47.07 | +3.22% |
| November 2026 | $30.09 | $36.66 | $46.66 | -1.87% |
| December 2026 | $28.91 | $35.45 | $45.52 | -3.33% |
Click any year to see its month-by-month SEPN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, SEPN could reach as high as $45.52, with a base case around $35.93 and support toward $23.09 — roughly 0% from $35.93. A consolidation phase looks the most probable path here.
Expect SEPN to range from $34.40 to $61.33 through 2027. The $44.45 average target implies a +24% move from current prices. That is up +24% on the projected 2026 average. Momentum favours further upside here.
The SEPN price prediction for 2028 points to an average of $49.71 (low $37.05, high $71.82) — a potential gain of +38% on today's $35.93. Buyers look set to stay in control over this stretch.
In 2029, SEPN is projected to trade between $40.27 and $83.50, averaging $55.75 — a potential gain of +55% from today's $35.93. That is up +12% on the projected 2028 average. Momentum favours further upside here.
Septerna, Inc.'s 2030 outlook centres on $72.11, within a $50.65 to $111.28 range. That is up +29% on the projected 2029 average. That marks a +101% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, SEPN could reach as high as $142.04, with a base case around $89.68 and support toward $61.39 — roughly +150% from $35.93. Momentum favours further upside here.
Expect SEPN to range from $74.82 to $181.49 through 2032. The $111.95 average target implies a +212% move from current prices. That is up +25% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The SEPN price prediction for 2033 points to an average of $127.58 (low $83.34, high $211.19) — a potential gain of +255% on today's $35.93. Momentum favours further upside here.
In 2034, SEPN is projected to trade between $81.89 and $216.19, averaging $128.11 — a potential gain of +257% from today's $35.93. That is up 0% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Septerna, Inc.'s 2035 outlook centres on $137.94, within a $86.35 to $236.95 range. That is up +8% on the projected 2034 average. That marks a +284% change versus current levels. Momentum favours further upside here.
By 2040, SEPN could reach as high as $510.59, with a base case around $276.06 and support toward $156.90 — roughly +668% from $35.93. Buyers look set to stay in control over this stretch.
Expect SEPN to range from $226.53 to $975.24 through 2050. The $474.19 average target implies a +12.2x move from current prices. That is up +72% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in SEPN today (≈ 27.831895 SEPN) could be worth
$13,197.7
+$12,197.7 (+1220%) by 2050 · US Dollar
Based on the average projected SEPN price of $474.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SEPNwould be worth at today's price.
$1,000 invested in SEPN on Jul 10, 2025 (≈ 85.616436 SEPN) would be worth
$3,076.2
+$2,076.2 (+207.6%) today · 3.08× · US Dollar
Based on a SEPN entry price of $11.68 vs. today's $35.93.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $34 | $1,056.76 | +5.7% |
| 1 month ago | $30.47 | $1,179.19 | +17.9% |
| 3 months ago | $23.09 | $1,556.08 | +55.6% |
| 6 months ago | $24.88 | $1,444.13 | +44.4% |
| 1 year ago | $11.68 | $3,076.2 | +207.6% |
| All time (1.7y) ago | $21.4 | $1,678.97 | +67.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SEPN forecast.
Our base-case forecast reaches $72.00 around 2030.
Implied market cap at $72.00: $3.25B
The multi-year forecast shows a strong long-term upside, with the average price rising from $44.74 in 2027 to $70.58 in 2030 and then higher through 2050 to $437.31.
Key long-horizon anchors include the 2030 average of $70.58 with an ROI of 93.9 and bullish sentiment, the 2040 average of $256.92 with an ROI of 605.8, and the 2050 average of $437.31 with an ROI of 1101.4. The max values for these years imply outsized upside in favorable scenarios, such as $108.64 in 2030 and $473.22 in 2040, culminating at $895.00 in 2050. While the trajectory suggests meaningful upside, these are estimates and not guarantees and depend on numerous market and sector factors.
Tap a question to reveal the answer.
2030 min $49.69, avg $70.58, max $108.64; ROI 93.9; sentiment BULLISH.
The forecast shows a bullish trajectory from 2027 onward, with rising average prices (44.74 in 2027 to 437.31 in 2050) and increasing ROI (up to 1101.4 by 2050). These are estimates, not guarantees.
Yes—the max forecast for 2030 is $108.64, with an average of $70.58 and a min of $49.69.
Current price: $36.40. Market cap: $1.64B.
Sentiment: BULLISH. RSI14: 60. SMA50: $30.18. SMA200: $26.01. Support: $29.79. Resistance: $37.34. 30-day range: $28.87 – $45.89. Annualized volatility: 70%.
Septerna, Inc. Community Discussion
0Share your Septerna, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.